Cerca Biotech’s Post

So, how prevalent is ecDNA in cancer? ecDNA are present in about 14% of cancer at diagnosis and up to 32% of advanced cancers, across multiple tumor types. That is one reason why Boundless is working tirelessly to bring transformative new medicines to patients with oncogene amplified cancer through ecDNA-directed therapies (ecDTx), making treatment more effective and offering new possibilities for patients to overcome this challenging disease. Learn more about the prevalence of ecDNA below. 

With prostate cancer being the second most common cancer in men and fourth most common overall, this #ProstateCancerAwarenessMonth we are highlighting the theme of "putting pressure on prostate cancer." Underscoring the need for relentless efforts in awareness, screening, and treatment is important not just for this month, but throughout the entire year. By increasing public knowledge about prostate cancer, promoting regular screenings, and utilizing advanced diagnostic tools, we can exert the necessary pressure to reduce the impact of this disease. Read our “Putting Pressure on Prostate Cancer” blog to learn how you can receive and achieve healthcare that empowers this Prostate Cancer Awareness Month: https://lnkd.in/gdusd-Xg #GEHealthCare #HealthcareThatEmpowers #Prostate

With prostate cancer being the second most common cancer in men and fourth most common overall, this #ProstateCancerAwarenessMonth we are highlighting the theme of "putting pressure on prostate cancer." Underscoring the need for relentless efforts in awareness, screening, and treatment is important not just for this month, but throughout the entire year. By increasing public knowledge about prostate cancer, promoting regular screenings, and utilizing advanced diagnostic tools, we can exert the necessary pressure to reduce the impact of this disease. Read our “Putting Pressure on Prostate Cancer” blog to learn how you can receive and achieve healthcare that empowers this Prostate Cancer Awareness Month: https://hubs.la/Q02Q0dLt0 #GEHealthCare #HealthcareThatEmpowers #Prostate

#ProstateCancerAwarenessMonth It’s crucial to push for year-round awareness, screenings, and improved treatments. By increasing public knowledge and promoting early detection, we can make a real impact.

One in every six deaths are caused by cancer globally. Today, we commemorate #WorldCancerDay to highlight the ongoing efforts in the medical sector to reduce cancer mortality. Axcelead's #drugdiscovery services contribute to the analysis of #cancer cells, as well as to evaluate drug responses leading to the development of treatments and cures for all types of cancers. We hope that our continuous oncological drug discovery services will lead to more remissions and positive outcomes in the future. Learn more about our #oncology related services here:　https://lnkd.in/g_6kbXNT

Like to share this Advancements 1. FDA Approvals: Between January and March 2024, the FDA issued 14 approvals for cancer indications, including the first ever regulatory approval for Tumor-Infiltrating Lymphocyte (TIL) therapy. 2. Improvements in Breast Cancer Treatment: Studies show that improvements in breast cancer screening and treatments have led to a significant reduction in breast cancer mortality. 3. Omission of Radiation in Select Cases: Trials are examining the omission of radiation in early, favorable-risk breast cancer. This could potentially lead to less invasive treatment protocols for certain patients. These advancements are not just about treating cancer, but about improving the quality of life for patients worldwide. #Oncology #HealthcareInnovation #CancerCare #healthcare #medicine #cancer

With prostate cancer being the second most common cancer in men and fourth most common overall, this #ProstateCancerAwarenessMonth we are highlighting the theme of "putting pressure on prostate cancer." Underscoring the need for relentless efforts in awareness, screening, and treatment is important not just for this month, but throughout the entire year. By increasing public knowledge about prostate cancer, promoting regular screenings, and utilizing advanced diagnostic tools, we can exert the necessary pressure to reduce the impact of this disease. Read our “Putting Pressure on Prostate Cancer” blog to learn how you can receive and achieve healthcare that empowers this Prostate Cancer Awareness Month: https://lnkd.in/dUK_BAUD #GEHealthCare #HealthcareThatEmpowers #Prostate

Technical review of ADCs for cancer therapies, including a brief discussion of the basics of ADCs, regulatory approach, overview, and technical complexities for quantification. The article summarizes recently approved ADCs and introduces the concepts of antibodies, linkers, and pay-loads. It also outlines cancer-specific ADCs currently in late-stage clinical trials for cancer treatment

Curious about how the Onco-PDO® test works? Check out our infographic to see the step-by-step workflow of this revolutionary cancer treatment approach! Here's a brief overview: Tumor cells are cultured into mini-organs in a 3D structure, known as Patient-Derived Organoids (PDOs). The drugs selected by physicians are then tested on the patient's individual mini-organs (PDOs) in the lab. Each treatment's response is analyzed, and a report is delivered within a clinically relevant timeframe, allowing doctors to make more informed decisions for personalized cancer treatment. Contact us to learn more about the Onco-PDO® test. #PrecisionOncology #Livingsciences #cancertreatment #CancerCare #OncoPDO #PersonalizedMedicine #InnovativeTreatment #BetterOutcomes Follow us on Facebook at https://lnkd.in/gtZqUqGb and Instagram at https://lnkd.in/gKJyHuvh to gain access to our novel approach to personalizing cancer; the Onco-PDO® test that will reshape the landscape of oncology.

Exciting news in the world of cancer treatment! The phase 2b KEYNOTE-942 trial has shown that combining Moderna's personalized mRNA-4157 cancer vaccine with Merck's pembrolizumab (Keytruda) significantly improves outcomes for high-risk melanoma patients. This combination therapy reduced the risk of recurrence or death by an impressive 44%, and patients experienced a meaningful improvement in recurrence-free and distant metastasis-free survival. The FDA has granted this combination Breakthrough Therapy Designation, and further phase 3 trials are underway. #Healthcare #mRNA #Melanoma #CancerResearch #ClinicalTrials